The relevance of RORC in leukemogenesis is further supported by the observed increased proliferation and apoptosis rates in mice deficient in the protein product of the RORC gene ROR , leading to the development of T-cell lymphoma 20 and lymphoblastic lymphoma 21 .
Taken together, deregulation of the RORC/Th17 axis can provide an explanation to both the oncogenic persistence of ATL and to patient susceptibility to opportunistic infections. In this study, we generate a representative consensus gene set for the RORC pathway of the Th17 axis and proceed to a systems biology analysis of novel and existing data to test the biological significance of this pathway in ATL.
Methods:
In silico analysis RORC expression levels were examined in publicly available transcriptomic data sets from patients with ATL, HTLV-1 infected asymptomatic controls, and healthy controls. A total of 135 untreated ATL patients, 12 HAM patients, 40 asymptomatic controls (AC), and 242 healthy controls (HC) from the Gene Expression Omnibus datasets GSE55851, GSE33615, GSE19080, GSE85487, and the European Genome-phenome archive EGAD1001411 dataset were used in this study ( Table 1 ). EGAD1001411 initially contained 45 ATL patients, but one outlier with an overall strongly divergent transcriptome was removed. The effect of age on RORC expression was investigated in the Healthy Estonian Cohort for healthy controls (n=293) and the UK Cohort for HTLV-1 infected individuals (n=30).
The Japanese Cohort #2 (EGAD1001411) RNA-Seq data was quality-and adapter-cleaned using trimmomatic 22 and cutadapt 23 and quantified with kallisto 24 using an index built on the transcriptome obtained from the Genome Reference Consortium GRCh38, rel79. CIBERSORT was used to generate an in silico approximation of the relative composition of 22 immune cell types in the samples 25 .
To facilitate consistent analysis of both the microarray and RNA-Seq data, the ensemble and/or Agilent IDs of the datasets were matched with corresponding Entrez IDs using the biomaRt package 26, 27 in R. The Entrez IDs were verified with the associated GPL files on GEO where available. Considering transcriptomic analysis of the Caribbean Cohort was performed on a limited (non-genome-wide) microarray platform, 2134 Entrez IDs were common to all examined microarrays and comprised the list of genes examined in this study. To address the bias in the measurements inherent to each platform, we adapted the quantile discretization method proposed by Warnat et al. 28 and transformed gene expression levels into percentile ranks among the surveyed 2134 genes for the meta-analysis. To further exclude the possibility of biasing our results, we refrain from making direct statistical comparisons of gene expression levels between datasets.
Published literature on RORc and ROR , as cited and detailed in the results section, was used to develop a consensus molecular pathway, which was then combined with the published ATL disease signature 29 to develop a gene set for further exploration.
Weighted Gene Correlation Network Analysis (WGCNA) 30 clusters genes into modules according to their topological overlap measure which quantifies how many gene-correlates were common to both members of each gene pair. To determine coherent gene modules and their correlation to clinical and molecular data, we performed WGCNA on each of the transcriptomic datasets from two independent ATL cohorts recently published by our group: in vitro gene expression data from short-term cultured ATL patient PBMCs (n=8, Brazilian Cohort) performed in parallel with lymphoproliferation, and ex vivo expression data from ATL patient PBMCs (n=44) of Japanese Cohort #2 29 . Module membership of the RORC gene set and the ATL signature genes were determined and correlated to demographic, clinical, and in vitro data.
In vitro analysis
Spontaneous lymphoproliferation and apoptosis of primary cells (PBMC) from ATL patients (n=8, Brazilian Cohort) was measured by [ 3 H]-thymidine incorporation, as described previously 31 .
Statistical analysis
Statistical analysis was performed using GraphPad Prism 7.0. Differences in RORC gene expression were analyzed by Kruskall-Wallis test for Japanese Cohorts #1 and #2, and the Caribbean Cohort. For Japanese Cohort #3, where ACs were not included, Mann-Whitney was used to compare HC and ATL patients. The false discovery rate two-stage method of Benjamini, Krieger, and Yekutieli was used to correct for multiple comparisons. Spearman's Rho was used to correlate gene expression (either per gene or per WGCNA module using their eigengene expression) to demographic (age), clinical data (patient survival) and in vitro data (proliferation and apoptosis).
Results:

Transcriptomic analysis of four independent cohorts reveals a RORC lo ex vivo phenotype in ATL
Gene expression profiling of ex vivo primary cells from ATL patients showed decreased RORC normalized expression in all four independent cohorts, revealing a common RORC lo phenotype ( Figure 1A -B-C-D). Japanese Cohort #3 (n=73) and Caribbean Cohort (n=38) had significant decreases in RORC expression of ATL patients (p<0.0001 and p=0.016 respectively).
Japanese Cohorts #1 (n=18) and #2 (n=50) had borderline significant decreases in RORC expression of ATL patients (p=0.083 and p=0.10). HAM patients in the Caribbean Cohort did not have a significant change in RORC expression (p=0.54), however asymptomatic HTLV-1 infected individuals (AC) did display a significant decrease in RORC expression (p=0.016) when compared to healthy controls. ACs in other cohorts were not found to have a significant change in RORC expression, relative to healthy controls. Thus, RORC expression, measured as normalized expression ( Fig. 1 ) and percentile rank (Suppl. Figure S1 ), is consistently lower in ATL than in HC, but varies among cohorts for AC. Since RORC gene expression had been previously shown to decrease in AC 32 , we performed a meta-analysis of the fold changes in RORC expression in all four cohorts, using both normalized expression and percentile ranks. Normalized gene expression allows for a comparison of the fold change in absolute RORC levels across cohorts but does not take into account the profound perturbation of the cellular transcriptome between healthy vs. leukemic CD4+ cells in AC and ATL patients, respectively. In contrast, percentile ranks are a measure of RORC expression relative to the overall transcriptome for each individual, which is more suitable for a comparison between divergent disease states. This was confirmed by two-way ANOVA, analyzing cohorts and disease status (HC-AC-ATL) as separate variables. Figure 1F 
RORC Expression is not influenced by Age in Healthy Controls but decreases with
Age in HTLV-1 Infected individuals
Since ATL usually occurs after several decades of HTLV-1 infection 5 and ROR t Tregs were shown to increase with age in mice 33 , , we investigated the effect of age upon RORC gene expression in healthy controls and HTLV-1-infected individuals from several cohorts. First, we examined paired CD4 + T-cells (n=293), CD8 + T-cells (n=283), and PBMC (n=77) microarray results from a cohort of healthy controls with sufficient power to study the effects of age (Healthy Estonian Cohort, Table 1 ). We found that RORC expression levels did not significantly change with age in CD4 + T-cells (r= 0.002, p= 0.45, Figure 3C ), CD8 + T-cells (r=0.0001, p= 0.86, Figure   3D ) or PBMC (r=0.0001, p=0.93), nor with gender (data not shown). In contrast, we found that RORC expression significantly decreased with age in HTLV-1 infected individuals without ATL, either AC and HAM/TSP patients (r=-0.57, p=0.0002, n=30 from UK Cohort, Figure 3A ). We observed a similar tendency of decreased RORC expression with age (r=-0.62), but this observation did not reach statistical significance levels (p=0.10), most probably due to the small size of this ATL cohort (n=8, Brazilian Cohort) ( Figure 3B ). Unfortunately, the age of ATL patients was not available for the larger Japanese cohort.
A minor RORC hi subgroup of ATL patients displays a unique CADM1 lo HBZ lo
phenotype RORC hi outliers (Rout Method 34 , Q=0.1%) were observed in the three Japanese cohorts, accounting for a total of 13 out of 108 ATL patients (12.04%), Therefore, we examined this phenotype more closely in the largest examined cohort (Japanese Cohort #2), where 7 outliers with a higher normalized RORC expression were identified ( Figure 1B ). The patients from this cohort were then split into two groups, according to their RORC levels, as shown in Figure 2 .
Interestingly, we noted that RORC expression was inversely associated with expression levels of pathognomonic ATL markers CADM1 and HBZ. Thus, RORC hi patients displayed significantly lower HBZ (p=0.0061) and CADM1 (p=0.045) levels, but similar expression levels of other ATL surface marker genes (CD4, CD25/IL2RA, CCR4) suggesting the RORC hi subgroup might represent a distinct, possibly clinically relevant, molecular subgroup of ATL. The lower CADM1 and HBZ expression levels in RORC hi patients may represent the decreased proliferation rate of chronic or less aggressive ATL subtypes. As shown in Supplementary Figure S2 , RORC hi patients showed similar expression levels of other ATL driver genes (STAT3, PLCG1, NFKB1, RELA, FAS) 29, 35 , highlighting the specificity of the RORC hi CADM1 lo HBZ lo phenotype. Positive expression of IRF4 and c-REL has been associated with resistance to IFN-ɑ + AZT therapy in ATL patients 35, 36 .
Interestingly, IRF4 and c-REL expression did not differ between RORC hi and RORC lo patients (Suppl. Figure S2 ). This finding suggests RORC expression is independent of IFN-ɑ + AZT therapeutic resistance and offers an additional molecular target for patients failing this therapy.
Definition of a consensus RORC pathway and gene set and its relevance to ATL oncogenesis
To facilitate the molecular exploration of the RORC hi phenotype, a RORC gene set was determined based on published literature findings, integrating the intrinsic oncogenic pathway for STAT3 activation, as defined by Yu et al. 37 , and RARA/RORC signaling summarized by Muranski and Restifo (2013) 38 . The consensus RORC pathway included IL6, IL23, IL21, IRF4, BATF, STAT1, STAT5, RARɑ, TGFβ, NF B, SLC2A1 (GLUT1), BCL6, STAT3, FOXP3, SOCS1, RORC, and IL17A/F. Figure 4 illustrates the interplay between these genes, as detailed in the legend. RNX1, T-bet, RORA, and TGFB1R were not measured by the microarray used for the initial WGCNA analysis on the Brazilian cohort (pilot cohort) and therefore excluded from the gene set.
Transcriptomic expression levels of RORC pathway members extracted from a UK HTLV-1 infected asymptomatic control dataset (UK Cohort; GSE29312) and ATL cohort (Japanese Cohort #2; EGAD1001411) showed that the majority were expressed at highly variable levels (Supplementary Figure S3 ). First, prominent STAT1 expression is in line with published findings in AC 32, 38 and ATL 35, 39, 40 . On the other hand, downstream members of the RORC pathway and particularly, IL17 family genes were either undetectable or poorly expressed.
WGCNA analysis of PBMCs from our pilot ATL cohort (n=8, Brazil, Figure 5A To confirm and extend these findings on proliferation, we repeated the WGCNA in the larger cohort of ATL patients (n=44, Japanese cohort #2). We additionally obtained in silico estimates of the relative size of 22 immune cell type populations using the CIBERSORT software 25 .
As shown in Figure 5B , RORC was the only pathway member which was significantly and positively correlated (r=0.42) with the presence of resting memory CD4 + T-cells (p=0.0041).
Downstream pathway members IL17B (r=0.62, p= 0.0000054) and IL17C (r=0.42, p=0.04) were positively correlated with the presence of naïve CD4 + T-cells. STAT3 inducer NFkB subunits 1 and 2 were negatively correlated with naïve CD4 + T-cells (p=0.02 and p=0.052 respectively) and resting memory CD4 + T-cells (p-0.000073 and p=0.00084 respectively). Similar to the observations in the WGCNA of the pilot cohort, a reverse trend was also seen in the CIBERSORT analysis between upstream and downstream members of the RORC pathway and their correlation with naïve and activated memory CD4+ T-cell fractions ( Figure 5B ). Together, the two WGCNA analyses, combined with CIBERSORT CD4+ subtype quantification, suggest a distinct change in proliferative pathways between upstream and downstream members of the RORC/IL17 pathway with opposite effects in activated memory vs. naïve and resting memory CD4+ T-cells. Among downstream pathway members, IL17C showed the strongest antiproliferative gene module membership in both cohorts and was also more frequently detected than other IL17 family members (IL17A/B/D/F). Therefore, we classified ATL patients from the largest cohort (Japanese cohort #2) into IL17C expressing, (IL17Cpos, n=17) and IL17C negative (IL17Cneg, n=28). As shown in Figure 5C , IL17C positive patients had significantly lower gene expression levels of proliferative marker PCNA (Mann-Whitney p=0.022) and in those patients, IL17C was positively correlated to RORC gene expression (r=0.54, p=0.026), confirming the findings of our modular analysis. To explore if the antiproliferative IL17C/PCNA link might be specific to ATL or shared with other leukemias, we analyzed two large cohorts of acute T-and B-cell leukemia (T-ALL, n=138; B-ALL, n=300). Similar to ATL, we found a significant negative correlation between IL17C and PCNA transcript levels in both T-ALL (r=-0.24, p=0.007) and B-ALL (r=-0.28, p<0.0001).
RORC expression is independent of viral HBZ and Tax mRNA
SLC2A1, STAT3, and NFkB1 are members of the proliferative module ( Figure 5 ) and upstream to RORC in the RORC pathway (Figure 4 ), of which NF B1 and STAT3 also belong to the mutational signature of ATL 29 . Therefore, we tested WGCNA module membership of two major HTLV-1 transcripts: HBZ and Tax, which are, respectively increased and decreased in ATL cells compared to asymptomatic controls [39] [40] [41] [42] . However, no overlap was found between the module memberships of RORC, HBZ, and Tax in the WGCNA of Japanese Cohort #2 (data not shown).
In addition, no RORC gene module members were significantly correlated to HBZ or Tax transcript levels, suggesting decreased RORC levels and signaling in ATL are not a direct consequence of retroviral transcription.
IFN-ɑ, IFN-β and Ascorbic Acid in vitro treatment differentially regulates RORC expression in primary ATL cells and HTLV-1 transformed cell lines.
We previously tested the effects of IFN-ɑ and Ascorbic Acid on HTLV-1 infected transformed cell lines (MT2, MT4, C8166) [41] [42] [43] . Although both these drugs have shown efficacy in decreasing HTLV-1-induced proliferation [41] [42] [43] [44] Supplementary Figure S5 . This is in agreement with our recently demonstrated differential anti-proliferative and pro-apoptotic effect of both IFN subtypes 31 .
Discussion:
Upon transcriptomic meta-analysis of four different cohorts, we found a specific and consistent RORC lo phenotype in primary ATL cells and to a lesser extent in HTLV-1-infected individuals, in contrast to healthy controls. In addition, HTLV-1-infected individuals displayed an age-dependent decrease in RORC expression. The observed two-step decrease of RORC in ACs and ATL patients might thus represent an early event in HTLV-1-driven leukemogenesis. We also identified a small subset (12.04%) of RORC hi ATL patients with significantly lower pathognomonic CADM1 and HBZ levels but similar levels of other ATL markers (CD4, CD25 and CCR4), hinting at a less aggressive ATL subtype.
ATL pathogenesis develops over decades as is seen by patients presenting at least 20 years after HTLV-1 infection; yet not all infected patients develop ATL. Observational studies suggest that ATL, at least in the Caribbean and Brazil, can be triggered by the pediatric cutaneous manifestation known as Infectious Dermatitis [45] [46] [47] [48] . ID is a chronic, eczematous condition with scaly, crusted lesions often superimposed by Staphylococcus aureus or Streptococcus pyogenes infections 45, 46 . Defects in the Th17 axis increase vulnerability to S. aureus and Candida albicans infections, whereas in vivo S. aureus primed memory Th17 cells inhibited IL-17 production and increased IL-10 production 47, 49 . Of interest, two recent papers have demonstrated a role for IL-10 as an unexpected proliferative trigger of infected CD4+ T-cell clones and, possibly, leukemogenesis 50, 51 . Corroborating these findings, IL10 was found to be a significant (r=0.36, p= 0.013) member of the proliferative module, together with PCNA and MKI67 in our WGCNA analysis. Therefore, our findings underscore an IL-10 vs. RORC/IL-17 antagonism in HTLV-1associated pathologies provides a possible molecular basis for the epidemiological link between ID and ATL, alteration of the RORC/Th17 axis, and subsequent progression to leukemogenesis.
Indeed, modular transcriptomic analysis in ATL shows a strong correlation of the RORC pathway with cell proliferation and possibly oncogenesis, which underscores its therapeutic potential.
WGCNA analysis combined with CIBERSORT suggested the involvement of RORC pathway members in the homeostasis of resting memory and naïve CD4+ T-cells. Combining the RORC lo observation in ATL cohorts with our WGCNA analysis, we find that decreased RORC expression is correlated with proliferation and ATL driver genes (STAT3, NF-kB). Thus, inducing RORC and switching to a RORC hi phenotype may convert ATL cells to a less aggressive subtype, suggested by the lower CADM1 and HBZ levels seen in the RORC hi subset (Figure 2 ). Inducing IL17 expression via RORC stimulation would also subsequently alter the host immune response to reduce the risk of opportunistic infections by increasing Th17 cell count. In addition, the strongest negative correlation observed in both ATL cohorts, between IL17C and proliferation marker PCNA, was replicated in two large cohorts of other acute lymphoid leukemias, namely T-ALL and B-ALL ( Figure 5D ). This indicates an antagonistic regulation between Th17 cells, usually considered as pro-inflammatory, and leukemic cell proliferation. Regarding the clinical translation of these results, antitumor immunotherapy using Th17 cells has recently shown promising results in animal models. Adoptive cell therapy using ex vivo Th17 cell selection enhanced antitumor activity 50, 52 , to a greater extent than Th1 cells and other CD4 + T-cells 50, 52 .
Although most often believed to antagonize IL17 production, IFN-β can trigger and even exacerbate IL17 production, especially in Th17-mediated inflammatory diseases 51, 53 . This becomes problematic in cases of multiple sclerosis, where 30-50% of patients are resistant to IFN-β therapy 51 .
However, this same exacerbation could be useful in ATL as a means of increasing Th17 cell production and decreasing proliferation of leukemic clones. IFN-β significantly alters the expression of more RORC pathway members than IFN-ɑ ( Supplementary Figure S5) , a common therapeutic adjuvant to zidovudine in ATL treatment. This finding, along with the observation that IFN-β has superior anti-proliferative and pro-apoptotic properties compared to IFN-ɑ 31 , makes IFNβ a novel, valuable option for combination therapy in ATL.
Recently, immune checkpoint inhibitors have come to the forefront of anticancer immunotherapy 52, 53 . Studies have suggested that inhibiting the transmembrane protein Programmed death ligand -1 (PD-L1) can increase Th17 cell count. Notably, human anti-PD-L1 antibodies restored IL-17A protein levels in naïve T-cells of patients with a loss-of-function STAT3 mutation [52] [53] [54] . Also noteworthy is the induction of Th17 cell differentiation by RORy agonist LYC-54143, which simultaneously reduced PD-1 + cell numbers and PD-1 expression in vitro, resulting in tumor growth inhibition in two murine models 55 . PD-L1 amplifications have been associated with worse prognosis in ATL patients, especially in aggressive subtypes 56 .
In conclusion, we describe a predominant RORc lo phenotype observed in four cohorts of ATL patients and a minor RORC hi molecular subgroup with significantly lower pathognomonic CADM1 and HBZ mRNA levels. An age-dependent decline in RORC level indicates a possible early event in HTLV-1-driven leukemogenesis, supported by modular transcriptomic analysis of ATL patients, revealing a strong negative correlation of the RORC/IL17 pathway with proliferation, which was shared with T-ALL and B-ALL patients. Thus, inducing RORC levels and/or signaling might represent (immuno)therapeutic benefit in ATL and possibly other acute lymphoid leukemias.
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